Results 91 to 100 of about 60,444 (298)
Patient Preference and Adherence, 2021 Robert S Epstein,1 Upal K Basu Roy,2 Matti Aapro,3 Tehseen Salimi,4 Donald Moran,4 JoAnn Krenitsky,1 Megan L Leone-Perkins,5 Cynthia Girman,6 Courtney Schlusser,7 Jeffrey Crawford8 1Epstein Health, LLC., Woodcliff Lake, NJ, USA; 2LUNGevity Foundation ...
Epstein RS +9 more
doaj
Promotion of myelopoiesis in myelosuppressed mice by Ganoderma lucidum polysaccharides
Frontiers in Pharmacology, 2012 Ganoderma lucidum polysaccharides (Gl-PS) exhibit potent immunomodulating effects. Immunomodulation plays an important role in hematopoiesis.
Xiao Ling Zhu +3 more
doaj +1 more source
Cancer Reports, 2022 Background The time‐limited combination of venetoclax and obinutuzumab (VenG) was established by the German CLL Study Group in the CLL14 trial for the upfront management of newly diagnosed chronic lymphocytic leukemia (CLL), showing a superior ...
Courtney Samuels +6 more
doaj +1 more source
Prospective study establishing a management plan for impacted third molar in patients undergoing hematopoietic stem cell transplantation [PDF]
, 2011 ObjectiveAlthough dental treatment before hematopoietic stem cell transplantation (HSCT) is essential to prevent serious infections from oral sources, the best management plan for impacted third molar (ITM) is unclear.Study designThis study was planned ...
Bukawa Hiroki +12 more
core +1 more source
SELECTIVE MYELOSUPPRESSION FOLLOWING YELLOW PHOSPHORUS INGESTION
Australasian Medical Journal, 2015 Toxicity from accidental and intentional ingestion of yellow phosphorus, ubiquitously present in fireworks and rodenticides, has recently become more frequent. Gastrointestinal, renal, neurologic, and cardiovascular manifestations are common, with mortality of 23 per cent to 73 per cent. Reports of haematological abnormalities are rare.
Aneesh, Basheer +3 more
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo +10 more
wiley +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials
, 2010 An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "phase I/II" trials, these experiments typically have the nominal scientific ...
Thall, Peter F.
core +1 more source
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. [PDF]
, 2000 A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse.
Albright, RE +21 more
core
British Journal of Clinical Pharmacology, EarlyView.Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon +13 more
wiley +1 more source